Przejdź do zawartości
Merck

M-106

Supelco

Mycophenolic acid solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C17H20O6
Numer CAS:
Masa cząsteczkowa:
320.34
Kod UNSPSC:
41116107
NACRES:
NA.24

klasa czystości

certified reference material

Postać

liquid

Właściwości

Snap-N-Spike®/Snap-N-Shoot®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

stężenie

1.0 mg/mL in acetonitrile

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

clinical testing

format

single component solution

temp. przechowywania

−70°C

ciąg SMILES

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+

Klucz InChI

HPNSFSBZBAHARI-RUDMXATFSA-N

informacje o genach

Opis ogólny

Assayed in therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range, mycophenolic acid is an immunosuppressant drug and the active metabolite of the prodrug mycophenolate mofetil. This analytical standard is suitable for LC-MS/MS applications including therapeutic drug monitoring and other clinical or diagnostic applications.

Zastosowanie


  • Targeted Inhibition in Gastrointestinal Toxicity: Mycophenolic acid is employed in targeted inhibition studies of gut bacterial β-glucuronidases to alleviate gastrointestinal toxicity caused by mycophenolate mofetil. This application is crucial for enhancing patient outcomes in immunosuppressive treatments, showcasing its value in pharmaceutical research (Xia et al., 2024).

  • Synergistic Immunosuppression Therapy: The solution′s use in combination with low dose systemic immunosuppression to sustain vascularized composite allograft survival highlights its potential in transplant medicine. This research underscores the critical role of mycophenolic acid in developing effective immunosuppressive protocols (Feturi et al., 2024).

  • Development of Genetic Markers: Mycophenolic acid′s biochemical properties are utilized in the development of genetic markers within Yarrowia lipolytica, demonstrating its importance in genetic engineering and biotechnological advancements (Zhu et al., 2024).

  • Fungicidal Compound Discovery: The compound is used to derive fungicidal hydrazide lead compounds from sinapic acid and mycophenolic acid, illustrating its application in agricultural biochemistry and the development of new antimicrobial agents (Fang et al., 2023).

Uwaga dotycząca przygotowania

This product contains an ampule of 1 mL, at a concentration of 1.0 mg/mL in acetonitrile.

Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
This page may contain text that has been machine translated.

Piktogramy

FlameExclamation mark

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

Klasyfikacja zagrożeń

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

35.6 °F - closed cup

Temperatura zapłonu (°C)

2 °C - closed cup


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

CD25 blockade for refractory polymyositis.
Nicolò Pipitone et al.
Clinical and experimental rheumatology, 31(3), 474-474 (2013-03-08)
David Wofsy et al.
Arthritis and rheumatism, 65(6), 1586-1591 (2013-03-27)
Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?
Jonathan J Hogan et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 692-693 (2013-04-16)
Nathan R Selden et al.
Journal of neurosurgery. Pediatrics, 11(6), 643-652 (2013-04-16)
Infantile and late-infantile neuronal ceroid lipofuscinoses (NCLs) are invariably fatal lysosomal storage diseases associated with defects in lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT-1) or tripeptidyl peptidase 1 (TPP1) activity. Previous preclinical studies have demonstrated that human CNS stem cells (HuCNS-SCs)
E Kieslichova et al.
Transplantation proceedings, 45(2), 770-777 (2013-03-19)
The diagnosis of sepsis is difficult in immunocompromised patients owing to their modified response to infection. Our experiment in minipigs was designed to compare responses to sepsis between experimental groups of septic minipigs with and without immunosuppression. Minipigs with identical

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej